Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia.
Travaglini S, Silvestrini G, Attardi E, Fanciulli M, Scalera S, Antonelli S, Maurillo L, Palmieri R, Divona M, Ciuffreda L, Savi A, Paterno G, Ottone T, Barbieri C, Maciejewski JP, Gurnari C, Ciliberto G, Voso MT. Travaglini S, et al. Among authors: voso mt. Leuk Res. 2024 Oct;145:107568. doi: 10.1016/j.leukres.2024.107568. Epub 2024 Aug 22. Leuk Res. 2024. PMID: 39180902 Free article.
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis.
Falconi G, Galossi E, Fabiani E, Pieraccioli M, Travaglini S, Hajrullaj H, Cerretti R, Palmieri R, Latagliata R, Maurillo L, Voso MT. Falconi G, et al. Among authors: voso mt. Sci Rep. 2022 Dec 8;12(1):21231. doi: 10.1038/s41598-022-24644-1. Sci Rep. 2022. PMID: 36481766 Free PMC article.
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia.
Battipaglia G, Vincenzi A, Falconi G, Fiore A, D'Agostino F, Iannotta R, Grimaldi F, Gurnari C, Galossi E, Crisà E, Bonello F, Scalia G, Izzo B, Voso MT, Pane F. Battipaglia G, et al. Among authors: voso mt. Curr Res Transl Med. 2023 Apr-Jun;71(2):103386. doi: 10.1016/j.retram.2023.103386. Epub 2023 Feb 26. Curr Res Transl Med. 2023. PMID: 36905702 No abstract available.
Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A. Musto P, et al. Among authors: voso mt. Br J Haematol. 2017 Jun;177(5):741-750. doi: 10.1111/bjh.14621. Epub 2017 Apr 17. Br J Haematol. 2017. PMID: 28419408 Free article.
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.
Liu YC, Kwon J, Fabiani E, Xiao Z, Liu YV, Follo MY, Liu J, Huang H, Gao C, Liu J, Falconi G, Valentini L, Gurnari C, Finelli C, Cocco L, Liu JH, Jones AI, Yang J, Yang H, Thoms JAI, Unnikrishnan A, Pimanda JE, Pan R, Bassal MA, Voso MT, Tenen DG, Chai L. Liu YC, et al. Among authors: voso mt. N Engl J Med. 2022 May 26;386(21):1998-2010. doi: 10.1056/NEJMoa2119771. N Engl J Med. 2022. PMID: 35613022 Free PMC article.
Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.
Pereira-Martins DA, Coelho-Silva JL, Weinhäuser I, Franca-Neto PL, Silveira DR, Ortiz C, Moreira-Aguiar A, Lima MM, Koury LC, de Melo RA, Glória AB, Fagundes EM, Lino BK, Pagnano K, Bittencourt R, Nunes E, Traina F, Figueiredo-Pontes L, Keating A, Tallman MS, Ribeiro RC, Dilon R, Ganser A, Sanz MA, Berliner N, Valk P, Löwenberg B, Ottone T, Noguera NI, Voso MT, Paoloni F, Fazi P, Ammatuna E, Huls G, Schuringa JJ, Rego EM, Lucena-Araujo AR. Pereira-Martins DA, et al. Among authors: voso mt. Br J Haematol. 2023 Jan;200(2):170-174. doi: 10.1111/bjh.18510. Epub 2022 Oct 20. Br J Haematol. 2023. PMID: 36263593
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
Roboz GJ, Montesinos P, Selleslag D, Wei A, Jang JH, Falantes J, Voso MT, Sayar H, Porkka K, Marlton P, Almeida A, Mohan S, Ravandi F, Garcia-Manero G, Skikne B, Kantarjian H. Roboz GJ, et al. Among authors: voso mt. Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19. Future Oncol. 2016. PMID: 26785287 Free PMC article.
319 results